Delivery Order SPE2DR25D3103-SPE2DR26F9V12
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,990.63 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as the...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of September 3, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under a larger contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $2,074.80 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitive award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,008.80 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of December 9, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of September 17, 2025. This non-set-aside contract utilizes firm fixed price pricing and represents a competitively awarded delivery order under the company's larger pharmaceutical supply framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,348.00 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of November 26, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger prime indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,530.62 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of September 17, 2025. This competitive award uses firm fixed pricing with no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Emgality 120 mg/ml pen injectors, valued at $3,458.00. This firm fixed-price contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 7, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Emgality 120 mg/mL pen injectors, valued at $1,556.10. This is a firm fixed-price delivery order with an ultimate completion date of August 29, 2025, and represents a non-competitive set-aside award. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9V12Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,551.65 to Amerisourcebergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors, with an ultimate completion date of January 7, 2026. This competitively awarded, firm fixed-price order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. This delivery order is issued under Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 through December 2031. This comprehensive IDC serves as the primary vehicle for supplying an extensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, and medical devices. Emgality is a CGRP monoclonal antibody used for migraine prevention, reflecting the breadth of therapeutic treatments available through this government contract vehicle for military treatment facilities and other federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 1/5/26 |